Blog

The depth, vision and progress of EVQLV

The depth, vision and progress of EVQLV

Our CEO, Andrew Satz, recently spoke at Columbia University School of General Studies' "Alumni in Action." The subject of his talk was artificial intelligence. One of the questions posed to Andrew was what we were doing outside of coronavirus, along with the long term...

read more
EVQLV’s Evolutionary Algorithm Explained

EVQLV’s Evolutionary Algorithm Explained

https://youtu.be/qIW1o8jgRsk Our technology works by taking an antibody sequence of interest and performing evolutionary modeled mutagenesis, mimicking the natural selection inherent to antibody VDJ recombination and affinity maturation. Using large amounts of public...

read more
Andrew Satz on the Talent Finders Podcast

Andrew Satz on the Talent Finders Podcast

EVQLV's CEO, Andrew Satz, joined Kerrin Black of the Talent Finders Podcast to discuss his entrepreneurial journey, some of the challenges facing AI for drug discovery, his legacy and much more. Give it a listen below. https://youtu.be/A2QoFVnD1Wc Timestamps: Andrew's...

read more
How does EVQLV’s technology work?

How does EVQLV’s technology work?

This is a clip from our event with BioIDEA: Biotech vs COVID-19. Our CEO, Andrew Satz, explains how our technology works, with specific attention to our work on COVID-19. Give it a listen below (transcription beneath video). Transcription: We use nearly a hundred...

read more
What we do and how we do it

What we do and how we do it

Below is a clip from Andrew Satz's (CEO, EVQLV) speech at the Flatiron School. He explains what we do at EVQLV and how we do it. In short, we use artificial intelligence (AI) to discover and optimize novel biologics. Our algorithm uses an evolutionary approach with...

read more

Pin It on Pinterest